# Estimation the Change in Liver Fibrosis Stage with Serial Measurement of Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients

**Authors:** Tsuguru Hayashi, Yohei Kooka, Jo Kanazawa, Tomoki Matsuda

PMC · DOI: 10.3390/ijms26199410 · 2025-09-26

## TL;DR

This study shows that changes in WFA+-M2BP levels in blood can track liver fibrosis progression or improvement in patients with metabolic dysfunction-associated liver disease.

## Contribution

The study demonstrates that WFA+-M2BP is a reliable non-invasive marker for tracking liver fibrosis changes over time in MASLD patients.

## Key findings

- ΔWFA+-M2BP levels significantly correlated with liver fibrosis stage changes (p < 0.01).
- ΔWFA+-M2BP was a significant predictor of fibrosis regression in multivariate analysis (odds ratio: 3.54).
- Other non-invasive fibrosis markers did not reflect fibrosis stage changes.

## Abstract

Assessment of liver fibrosis stage is important in the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, non-invasive methods to determine the changes in liver fibrosis stage are unknown. We investigated whether Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+-M2BP), a serum fibrosis marker, can evaluate the changes in liver fibrosis stage. We observed the course of liver fibrosis stage and five serum fibrosis markers of 196 MASLD patients who had a paired biopsy performed. The changes in fibrosis markers, including WFA+-M2BP, were compared according to the changes in fibrosis stage. Factors associated with improvement of fibrosis stage were examined in a multivariate analysis. The changes in WFA+-M2BP (ΔWFA+-M2BP) were significantly correlated with changes in fibrosis stage (p < 0.01). The median of ΔWFA+-M2BP was −0.21, −0.08, −0.04, and 0.19 in 2 fibrosis stage regression group, 1 fibrosis stage regression group, fibrosis stage unchanged group, and fibrosis stage progression group, respectively (p < 0.01). However, other non-invasive markers did not reflect changes in fibrosis. ΔWFA+-M2BP was a significant factor for the regression of liver fibrosis stage in multivariate analysis (odds ratio: 3.54, 95% confidence interval: 1.55–8.12, p < 0.01). Time-course changes in WFA+-M2BP levels indicate the changes in liver fibrosis.

## Linked entities

- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), MASLD (MONDO:0013209)

## Full-text entities

- **Genes:** LGALS3BP (galectin 3 binding protein) [NCBI Gene 3959] {aka 90K, BTBD17B, CyCAP, M2BP, MAC-2-BP, TANGO10B}
- **Diseases:** Liver Fibrosis (MESH:D008103), MASLD (MESH:D008107), fibrosis (MESH:D005355)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12524841/full.md

---
Source: https://tomesphere.com/paper/PMC12524841